

Subject Index

- AIDS**, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, Amphotericin B methyl ester, 243
- AIDS**, Soluble CD4, sCD4-183, sCD4-PE40, HIV, *Pseudomonas* exotoxin A, 267
- AIDS**, ZDV, Interferon beta, Chromosomal damage, 205
- AZT**, Animal model of HIV infection, Friend virus, Chemoprophylaxis, 163
- Acyclovir**, Ribavirin, Combination chemotherapy, HSV-1, PRV, Keratitis, 151
- Adenovirus**, (S)-HPMPC, (S)-HPMPA, 2'-nor-cyclic GMP, 11
- Amphotericin B methyl ester**, Human immunodeficiency virus type 1 (HIV-1), Sulfated amphotericin B, AIDS, 243
- Animal model of HIV infection**, AZT, Friend virus, Chemoprophylaxis, 163
- Anthraquinone**, Hypericin, Emodin, Virucidal, Tween-80, 185
- Antibody-dependent enhancement**, HIV, U937, Neutralization, Carbohydrate, 231
- Antitherpetic agent**, Polyoxometalate, PM-19, Keggin-type structure, 327
- Antisense**, Drug development, Oligonucleotide, Translation arrest, Transcription arrest, 121
- Antiviral therapy**, Azidothymidine, Zidovudine, MAIDS, LP-BM5, MuLV, 307
- Azidothymidine**, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307
- BVDU**, HSV-1 keratitis, TK — HSV-1, HPMPA, HPMPA, PMEA, Phosphonylmethoxyalkyl derivative, 93
- Carbohydrate**, HIV, U937, Neutralization, Antibody-dependent enhancement, 231
- Cellular uptake**, HPMPA, PMEA, Endocytosis, Nucleoside transport, 115
- Chemoprophylaxis**, AZT, Animal model of HIV infection, Friend virus, 163
- Chemotherapy**, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Nucleoside analog, 29
- Chromosomal damage**, ZDV, Interferon beta, AIDS, 205
- Clavulone**, Vesicular stomatitis virus, Prostaglandin, 341
- Combination chemotherapy**, Acyclovir, Ribavirin, HSV-1, PRV, Keratitis, 151
- Cytomegalovirus**, HPMPA, DNA integrity, 41
- Cytomegalovirus**, Herpes, 7-Deaza adenosine, Pyrolopyrimidine, Nucleoside, 135
- 7-Deaza adenosine**, Cytomegalovirus, Herpes, Pyrolopyrimidine, Nucleoside, 135
- DNA hybridization**, Human cytomegalovirus, Flow cytometry, 1
- DNA integrity**, Cytomegalovirus, HPMPA, 41
- Dendritic keratitis**, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
- Drug development**, Antisense, Oligonucleotide, Translation arrest, Transcription arrest, 121
- dUTPase**, Herpes simplex virus, Mercurithio-deoxyuridine analog, 197
- Emodin**, Anthraquinone, Hypericin, Virucidal, Tween-80, 185
- Endocytosis**, HPMPA, PMEA, Cellular uptake, Nucleoside transport, 115
- Equine herpesvirus-1**, EHV-1, Resistance, Phosphonyl, Nucleoside analog, Chemotherapy, 29
- FeLV-FAIDS**, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, 78
- Feline leukemia virus**, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
- Flow cytometry**, Human cytomegalovirus, DNA hybridization, 1
- Friend virus**, AZT, Animal model of HIV infection, Chemoprophylaxis, 163
- HIV**, Human immunodeficiency virus, Moloney murine sarcoma virus, MSV, Single dose administration, 53
- HIV**, Ozone, Noncytotoxic, Virus inhibitor, 279
- HIV**, Proteinase, Inhibitor, 295
- HIV**, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, *Pseudomonas* exotoxin A, 265
- HIV**, U937, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231
- HIV-1**, TIBO, HIV-2, Reverse transcriptase, Novel RNA template, 255
- HIV-2**, TIBO, HIV-1, Reverse transcriptase, Novel RNA template, 255
- HPMPA**, HSV-1 keratitis, TK — HSV-1, BVDU, HPMPA, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HPMPA**, PMEA, Cellular uptake, Endocytosis, Nucleoside transport, 115

- HPMPC therapy**, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, PMEA therapy, 102
- HPMPC**, Cytomegalovirus, DNA integrity, 41
- HPMPC**, HSV-1 keratitis, TK – HSV-1, BVDU, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HPMPC**, Simian varicella virus, Monkey, 17
- HSV-1 keratitis**, TK – HSV-1, BVDU, HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93
- HSV-1**, Acyclovir, Ribavirin, Combination chemotherapy, PRV, Keratitis, 151
- Herpes simplex virus**, dUTPase, Mercurithio-deoxyuridine analog, 197
- Herpes simplex virus**, Dendritic keratitis, Recurrent ocular herpetic disease, Thymidine kinase, Virus inhibitor, 225
- Herpes**, Cytomegalovirus, 7-Deaza adenosine, Pyrrolopyrimidine, Nucleoside, 135
- Human cytomegalovirus**, DNA hybridization, Flow cytometry, 1
- Human immunodeficiency virus**, HIV, Moloney murine sarcoma virus, MSV, Single dose administration, 53
- Human immunodeficiency virus type 1 (HIV-1)**, Sulfated amphotericin B, Amphotericin B methyl ester, AIDS, 243
- Hypericin**, Anthraquinone, Emodin, Virucidal, Tween-80, 185
- Immunodeficiency**, Feline leukemia virus, 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), Retrovirus, FeLV-FAIDS, 78
- Inhibitor**, HIV, Proteinase, 295
- Interferon**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interleukin-1, Interleukin-2, 65
- Interferon beta**, ZDV, Chromosomal damage, AIDS, 205
- Interleukin-1**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-2, 65
- Interleukin-2**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, 65
- Keratitis**, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, PRV, 151
- Keggin-type structure**, Polyoxometalate, PM-19, Antiherpetic agent, 327
- LP-BM5**, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, MuLV, 307
- MAIDS**, Azidothymidine, Zidovudine, Antiviral therapy, LP-BM5, MuLV, 307
- MAIDS**, Murine acquired immunodeficiency syndrome, Opportunistic infection, HPMPC therapy, PMEA therapy, 102
- MSV**, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, Single dose administration, 53
- Mercurithio-deoxyuridine analog**, Herpes simplex virus, dUTPase, 197
- Moloney murine sarcoma virus**, Human immunodeficiency virus, HIV, MSV, Single dose administration, 53
- Monkey**, Simian varicella virus, HPMPC, 17
- MuLV**, Azidothymidine, Zidovudine, MAIDS, Antiviral therapy, LP-BM5, 307
- Murine acquired immunodeficiency syndrome**, MAIDS, Opportunistic infection, HPMPC therapy, PMEA therapy, 102
- NK cytotoxicity**, Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, Interferon, Interleukin-1, Interleukin-2, 65
- Neutralization**, HIV, U937, Antibody-dependent enhancement, Carbohydrate, 231
- Noncytotoxic**, HIV, Ozone, Virus inhibitor, 279
- Novel RNA template**, TIBO, HIV-1, HIV-2, Reverse transcriptase, 255
- Nucleoside analog**, Equine herpesvirus-1, EHV-1, Resistance, Phosphonyl, Chemotherapy, 29
- Nucleoside analog**, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65
- Nucleoside transport**, HPMPC, PMEA, Cellular uptake, Endocytosis, 115
- Nucleoside**, Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyrrolopyrimidine, 135
- Oligodeoxynucleotide**, Phosphorothioate modification, Protein synthesis inhibition, Replication inhibition, 173
- Oligonucleotide**, Antisense, Drug development, Translation arrest, Transcription arrest, 121
- Opportunistic infection**, Murine acquired immunodeficiency syndrome, MAIDS, HPMPC therapy, PMEA therapy, 102
- Ozone**, HIV, Noncytotoxic, Virus inhibitor, 279
- 9-(2-Phosphonylmethoxyethyl)adenine (PMEA)**, Feline leukemia virus, Immunodeficiency, Retrovirus, FeLV-FAIDS, 78
- 9-(2-phosphonylmethoxyethyl)adenine**, Nucleoside analog, NK cytotoxicity, Interferon, Interleukin-1, Interleukin-2, 65
- PM-19**, Polyoxometalate, Keggin-type structure, Antiherpetic agent, 327

- PMEA therapy**, Murine acquired immunodeficiency syndrome, MAIDS, Opportunistic infection, HPMPC therapy, 102
- PMEA, HMPA**, Cellular uptake, Endocytosis, Nucleoside transport, 115
- PMEA, HSV-1 keratitis, TK – HSV-1, BVDU, HMPA, HPMPC**, Phosphonylethoxymethyl derivative, 93
- PRV**, Acyclovir, Ribavirin, Combination chemotherapy, HSV-1, Keratitis, 151
- Phosphonyl**, Equine herpesvirus-1, EHV-1, Resistance, Nucleoside analog, Chemotherapy, 29
- Phosphonylethoxymethyl derivative**, HSV-1 keratitis, TK – HSV-1, BVDU, HMPA, HPMPC, PMEA, 93
- Phosphorothioate modification**, Oligodeoxynucleotide, Protein synthesis inhibition, Replication inhibition, 173
- Polyoxometalate**, PM-19, Keggin-type structure, Antiherpetic agent, 327
- Prostaglandin**, Vesicular stomatitis virus, Clavulone, 341
- Protein synthesis inhibition**, Phosphorothioate modification, Oligodeoxynucleotide, Replication inhibition, 173
- Proteinase**, HIV, Inhibitor, 295
- Pseudomonas* exotoxin A, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV, 265
- Pyrrolopyrimidine**, Cytomegalovirus, Herpes, 7-Deaza adenosine, Nucleoside, 135
- Rational screening program**, Rhinovirus, Screening, antiviral, 213
- Recurrent ocular herpetic disease**, Dendritic keratitis, Herpes simplex virus, Thymidine kinase, Virus inhibitor, 225
- Replication inhibition**, Phosphorothioate modification, Oligodeoxynucleotide, Protein synthesis inhibition, 173
- Resistance**, Equine herpesvirus-1, EHV-1, Phosphonyl, Nucleoside analog, Chemotherapy, 29
- Retrovirus**, Feline leukemia virus, 9-(2-Phosphonylethoxyethyl)adenine (PMEA), Immunodeficiency, FeLV-FAIDS, 78
- Reverse transcriptase**, TIBO, HIV-1, HIV-2, Novel RNA template, 255
- Rhinovirus**, Rational screening program, Screening, antiviral, 213
- Ribavirin**, Acyclovir, Combination chemotherapy, HSV-1, PRV, Keratitis, 151
- Screening**, antiviral, Rational screening program, Rhinovirus, 213
- (S)-HMPA, 2'-nor-cyclic GMP, (S)-HPMPC**, Adenovirus, 11
- (S)-HMPA, (S)-HPMPC, 2'-nor-cyclic GMP, Adenovirus, 11**
- sCD4-183**, Soluble CD4, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- sCD4-PE40**, Soluble CD4, sCD4-183, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- Simian varicella virus**, HPMPC, Monkey, 17
- Single dose administration**, Human immunodeficiency virus, HIV, Moloney murine sarcoma virus, MSV, 53
- Soluble CD4**, sCD4-183, sCD4-PE40, AIDS, HIV, *Pseudomonas* exotoxin A, 265
- Sulfated amphotericin B**, Human immunodeficiency virus type 1 (HIV-1), Amphotericin B methyl ester, AIDS, 243
- TIBO**, HIV-1, HIV-2, Reverse transcriptase, Novel RNA template, 255
- TK – HSV-1, HSV-1 keratitis, BVDU, HMPA, HPMPC, PMEA**, Phosphonylethoxymethyl derivative, 93
- Thymidine kinase**, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Virus inhibitor, 225
- Transcription arrest**, Antisense, Drug development, Oligonucleotide, Translation arrest, 121
- Translation arrest**, Antisense, Drug development, Oligonucleotide, Transcription arrest, 121
- Tween-80**, Anthraquinone, Hypericin, Emodin, Virucidal, 185
- U937**, HIV, Neutralization, Antibody-dependent enhancement, Carbohydrate, 231
- Vesicular stomatitis virus**, Prostaglandin, Clavulone, 341
- Virucidal**, Anthraquinone, Hypericin, Emodin, Tween-80, 185
- Virus inhibitor**, Dendritic keratitis, Herpes simplex virus, Recurrent ocular herpetic disease, Thymidine kinase, 225
- Virus inhibitor**, HIV, Ozone, Noncytotoxic, 279
- ZDV**, Interferon beta, Chromosomal damage, AIDS, 205
- Zidovudine**, Azidothymidine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307